Abstract Library

#4575 Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase II, randomised, parallel-group study

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for the treatment of carcinoid syndrome (CS).

Conference:

Presenting Author: Hajac L

Authors: Hajac L, Chauhan A, Mohamed A, Usiskin K, Mui C,

Keywords: paltusotine, phase 2 trial, somatostatin receptor agonist, safety, carcinoid syndrome,

#4487 Fast pancreatic cancer diagnosis using lightweight Mamba framework

Introduction: Pancreatic cancer is a deadly malignancy often diagnosed too late for effective treatment. Fast and precise identification of pathological regions in histopathology images is essential but limited by current slow methods. We present a framework to accelerate this process and enhance diagnostic support.

Conference:

Presenting Author:

Authors: Shengzhe Y, Yan K,

Keywords: Pancreatic Cancer, Lightweight Mamba Architecture, Pathology Region Classification and Recognition,

#4427 Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) as second-line and maintenance therapy for neuroendocrine carcinoma with liver metastases: A single-arm, open-label, single-centre phase II clinical study (SuHaNec)

Introduction: Neuroendocrine carcinoma (NEC) is rare and highly aggressive, and liver metastasis leads to worse outcomes for patients (pts) with limited treatment options and poor prognosis. Surufatinib (SUR) exhibited promising antitumour activity in neuroendocrine neoplasms.

Conference:

Presenting Author:

Authors: Wang Y, Wang J, Yang D, Yao W, Zhang N,

Keywords: neuroendocrine carcinoma, surufatinib, hepatic artery infusion chemotherapy, later-line treatment,

#4049 A prospective, open-label study evaluating the efficacy and safety of Surufatinib (S) in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNET)

Introduction: Surgery is the primary treatment and only possible cure for pNET. Unresectable pNET necessitates conversion therapy to obtain opportunity of radical resection. Former trials have shown potential of Surufatinib (S) and CAPTEM as conversion therapy in pNET.

Conference:

Presenting Author: Wang Z

Authors: Wang Z, Cao D, Ke N,

Keywords: pNET, Conversion therapy, Surufatinib, CAPTEM,

#3949 Real-world study of Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) for high-grade neuroendocrine neoplasm

Introduction: Current therapeutic schedules of liver metastasis-dominated extrapulmonary high-grade neuroendocrine neoplasm (HG-NEN) have limited clinical benefits and liver metastasis progression is the main cause of death. Surufatinib (SUR, a selective VEGFRs, FGFR1 and CSF-1R inhibitor) showed promising antitumor activity in neuroendocrine neoplasm.

Conference:

Presenting Author:

Authors: Wang Y, Yu H, Yang D, Liu H, Yao W,

Keywords: Real-world study, surufatinib, hepatic artery infusion chemotherapy, high-grade neuroendocrine neoplasm,